Literature DB >> 1979953

Taxol treatment of experimental proliferative vitreoretinopathy.

S A Daniels1, K G Coonley, M O Yoshizumi.   

Abstract

Taxol is a potent stabilizer of microtubules, and inhibitor of in vitro replication, migration, and contraction of fibroblasts. It has been found to limit the development of experimental tractional retinal detachments in nonvitrectomized rabbit eyes. We used taxol in vitrectomized, phakic rabbit eyes with experimentally induced proliferative vitreoretinopathy and tractional retinal detachments. Taxol was dissolved in 30% DMSO because of poor aqueous solubility. A single 0.1 ml intravitreal dose of 2 x 10(-4) M taxol in 30% DMSO was injected immediately after 250,000 heterologous corneal fibroblasts had been injected; 0.1 ml of 30% DMSO was injected into control eyes. Taxol reduced the incidence of tractional retinal detachments seen 3-4 weeks later. When taxol injection was delayed for 3 days after the initial intravitreal injection of fibroblasts into nonvitrectomized eyes, the extent of retinal detachments was reduced, but the incidence of retinal detachment was unchanged from the untreated eyes at the end of 4 weeks. These data indicate that taxol may be most useful when given early in the course of proliferative vitreoretinopathy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979953     DOI: 10.1007/bf00918482

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  14 in total

1.  Glucocorticosteroid inhibition of intraocular proliferation after injury.

Authors:  Y Tano; D B Chandler; B W McCuen; R Machemer
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

2.  5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite.

Authors:  M Blumenkranz; E Hernandez; A Ophir; E W Norton
Journal:  Ophthalmology       Date:  1984-02       Impact factor: 12.079

3.  The role of cellular proliferation in an experimental model of massive periretinal proliferation.

Authors:  D M Fastenberg; K R Diddie; K Dorey; S J Ryan
Journal:  Am J Ophthalmol       Date:  1982-05       Impact factor: 5.258

4.  Taxol for the treatment of proliferative vitreoretinopathy.

Authors:  F M van Bockxmeer; C E Martin; D E Thompson; I J Constable
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-08       Impact factor: 4.799

5.  Surgical removal of vitreous. Its effect on intraocular fibroblast proliferation in the rabbit.

Authors:  H T Hsu; K Dorey; N Sorgente; S J Ryan
Journal:  Arch Ophthalmol       Date:  1984-04

6.  Oral colchicine for the treatment of experimental traction retinal detachment.

Authors:  M Lemor; J H Yeo; B M Glaser
Journal:  Arch Ophthalmol       Date:  1986-08

7.  The classification of retinal detachment with proliferative vitreoretinopathy.

Authors: 
Journal:  Ophthalmology       Date:  1983-02       Impact factor: 12.079

8.  Fluorouracil for the treatment of massive periretinal proliferation.

Authors:  M S Blumenkranz; A Ophir; A J Claflin; A Hajek
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258

9.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.

Authors:  M Kirmani; M Santana; N Sorgente; P Wiedemann; S J Ryan
Journal:  Retina       Date:  1983 Fall-Winter       Impact factor: 4.256

View more
  9 in total

1.  Comparative transcriptomic analysis reveals adriamycin-induced apoptosis via p53 signaling pathway in retinal pigment epithelial cells.

Authors:  Yu-Chen Lin; Ze-Ren Shen; Xiao-Hui Song; Xin Liu; Ke Yao
Journal:  J Zhejiang Univ Sci B       Date:  2018 Dec.       Impact factor: 3.066

2.  Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes.

Authors:  Murat Atabey Ozer; Nihat Polat; Serkan Ozen; Tevfik Ogurel; Hakan Parlakpinar; Nigar Vardi
Journal:  Int Ophthalmol       Date:  2016-08-05       Impact factor: 2.031

3.  Paclitaxel-Releasing Thin Biodegradable Film for Prevention of Bleb Avascularity Without Compromising Filtration in Rabbits.

Authors:  Tetsuhiko Okuda; Tomomi Higashide; Mayumi Sakurai; Yukako Fukuhira; Hiroaki Kaneko; Masatsugu Shimomura; Kazuhisa Sugiyama
Journal:  Transl Vis Sci Technol       Date:  2015-06-11       Impact factor: 3.283

Review 4.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

5.  Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study.

Authors:  C H Kon; R H Asaria; N L Occleston; P T Khaw; G W Aylward
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

6.  Dimethyl sulphoxide dose-response on rat retinal function.

Authors:  Tina I Tsai; Bang V Bui; Algis J Vingrys
Journal:  Doc Ophthalmol       Date:  2009-09-11       Impact factor: 2.379

7.  Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes.

Authors:  Nikolai Gross; Mahdy Ranjbar; Charlotte Evers; Jing Hua; Gottfried Martin; Brita Schulze; Uwe Michaelis; Lutz L Hansen; Hansjürgen T Agostini
Journal:  Mol Vis       Date:  2013-01-10       Impact factor: 2.367

8.  Proliferative vitreoretinopathy: current and emerging treatments.

Authors:  Ama Sadaka; Gian Paolo Giuliari
Journal:  Clin Ophthalmol       Date:  2012-08-14

9.  Use of caffeic acid phenethyl ester and cortisone may prevent proliferative vitreoretinopathy.

Authors:  Yusuf Turkoz; Hamdi Er; Mehmet Borazan; Harun Yilmaz; Bülent Mizrak; Hakan Parlakpinar; Yilmaz Cigremis
Journal:  Mediators Inflamm       Date:  2004-04       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.